



CURING INFECTIONS.
 TREATING CHRONIC ILLNESS.
 IMPROVING QUALITY OF LIFE.
 CREATING TOMORROW'S ANTIBIOTICS.

www.cempra.com

Corporate fact sheet

Summer 2010

Corporate Overview

Founded in 2006, Cempra Pharmaceuticals develops differentiated antibacterials to address the increasing challenge of drug-resistant pathogens. Cempra's two clinical-stage candidates, solithromycin (CEM-101) and TAKSTA™ (CEM-102, fusidic acid), address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and community. Cempra has leveraged its macrolide library of more than 500 compounds to identify solithromycin as well as non-antibacterial macrolide leads to treat chronic illnesses such as inflammatory diseases, endocrine diseases and gastric motility disorders.

Antibiotic Resistance and Opportunity

Antibiotic resistance has been a rising threat to human health for several years. Effectiveness of many antibacterial agents has declined worldwide limiting physicians' options to treat serious infections. Adding to the threat is a decline in discovery and development of new and novel antibiotics that target resistant pathogens by the pharmaceutical industry. Antibiotic drug resistance has a significant impact on mortality and contributes heavily to healthcare system costs worldwide. The World Health Organization has stated that antibiotic resistance is one of the greatest healthcare challenges for the future. Cempra is focused on developing solutions to this problem and addressing the future needs of patients through development of two novel clinical-stage candidates: solithromycin for CABP and TAKSTA™ for aBSSI.

Management Team

Prabhavathi Fernandes, Ph.D., Founder, Pres. & CEO
 Mark W. Hahn, EVP, Chief Financial Officer
 J. Carl Craft, M.D., Head of Medical Affairs
 Drusilla Scott, Ph.D., R.A.C., Sen. VP of Regulatory Affairs
 Thorsten P. Degenhardt, Ph.D., VP of Drug Development
 Donald C. Olsen, EVP, Business Development
 David Pereira, Ph.D., Vice President of Chemistry

Board of Directors

Garheng Kong, M.D., Ph.D., M.B.A., Chairman
 Geeta Vemuri, Ph.D.
 Wistar Morris III, B.A., M.B.A.
 Dov A. Goldstein, M.D., M.B.A.
 John H. Johnson
 Michael L. Corrado, M.D., F.I.D.S.A.
 Prabhavathi Fernandes, Ph.D., President and CEO


Scientific Advisory Board

Richard J. White, Ph.D., Chairman
 Paul G. Ambrose, Pharm. D., F.I.D.S.A.
 Christopher M. Cimarusti, Ph.D.
 J. Carl Craft, M.D.
 Sherwood L. Gorbach, M.D.
 David Krause, M.D.
 Ronald N. Jones, M.D.
 Ronald Nardi, Ph.D.
 André G. Pernet, Ph.D., M.B.A.
 Peter S. Ringrose, Ph.D.
 James V. Heck, Ph.D.
 Yoshi Ichikawa, Ph.D., Optimer Representative

Investors

Intersouth Partners
 Quaker BioVentures
 Devon Park Bioventures
 Teachers Private Capital
 Aisling Capital
 Wistar Morris III – Investment Banker

The Pipeline



Cempra also has a portfolio of pre-clinical macrolides without antibacterial activity for use as anti-inflammatory agents in treating COPD, psoriasis etc.

*Community Acquired Bacterial Pneumonia **Acute Bacterial Skin Structure Infections

Corporate Headquarters:

Cempra Pharmaceuticals
 Building Four Quadrangle
 6340 Quadrangle Drive, Suite 100
 Chapel Hill, NC 27517
 (919) 467-1716

Media Inquiries:

Russo Partners, LLC
 Robert E. Flamm, Ph.D.
 (212) 845-4226
robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
 (212) 845-4251
tony.russo@russopartnersllc.com